Press Releases 2021

  • Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

    Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Go to Liminal BioSciences Q1 2021 Results Conference Call on Tuesday May 18, 2021 8:30 AM EST

    View Now
  • Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion

    Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion

    Read Article
  • Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

    Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

    Read Article
  • Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

    Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

    Read Article
  • Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

    Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

    Read Article
  • Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

    Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

    Read Article
  • Liminal BioSciences Reports First Quarter 2021 Financial Results

    Liminal BioSciences Reports First Quarter 2021 Financial Results

    Read Article
  • Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

    Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

    Read Article
  • Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

    Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

    Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

    Read Article
  • Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

    Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

    LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.

    Read Article
  • Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

    Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

    Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.

    Read Article
  • loading
    Loading More...